Meeting
2016 ASCO Annual Meeting
Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor.
Authors
Shiraj Sen
The University of Texas MD Anderson Cancer Center, Houston, TX
Shiraj Sen , Arvind Rao , Filip Janku , David S. Hong , Apostolia Maria Tsimberidou , Sarina Anne Piha-Paul , John Heymach , Lauren Averett Byers , Funda Meric-Bernstam , Vivek Subbiah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2546)
DOI
10.1200/JCO.2016.34.15_suppl.2546
Abstract #
2546
Poster Bd #
246
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.
First Author: Ramya Thota
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC).
First Author: Anwaar Saeed
Poster
2016 ASCO Annual Meeting
Comparative molecular analyses of BRAF-V600E mutant tumors: Colorectal cancers (CRC) vs. melanomas.
First Author: Shelly Ann Christiansen
Poster
2014 ASCO Annual Meeting
Molecular evaluation of primary tumor (PT) and synchronous liver metastasis in colorectal cancer (srLmCRC) patients after cetuximab-based chemotherapy.
First Author: Daniela Adua